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 ABSTRACT 
 In most mammals, prolactin (PRL) is essential for 
maintaining lactation, and yet the short-term sup-
pression of PRL during established lactation by bro-
mocriptine has produced inconsistent effects on milk 
yield in cows and goats. To assess the effect of the 
long-term inhibition of PRL release in lactating dairy 
cows, 5 Holstein cows in early lactation received daily 
intramuscular injections of 1 mg of the PRL-release 
inhibitor quinagolide for 9 wk. Four control cows re-
ceived the vehicle (water) only. During the last week of 
the treatments, one udder half was milked once a day 
(1×) and the other twice a day (2×). Blood samples 
were harvested at milking in wk −1, 1, 4, and 8. The 
daily injections of quinagolide reduced milking-induced 
PRL release but not the basal PRL concentration. Qui-
nagolide induced a faster decline in milk production, 
which was about 5.3 kg/d lower in the quinagolide-
treated cows during the last 4 wk of treatment. During 
wk 9, the inhibition of milk production by quinagolide 
was maintained in the udder half that was milked 2× 
but not in the half milked 1×. Milk production was sig-
nificantly correlated with the quantity of PRL released 
at milking. Quinagolide did not affect the release of 
oxytocin at milking. Serum concentration of insulin-
like growth factor-1 was not affected by treatment or 
correlated with milk production. Serum concentrations 
of leptin and the calciotropic hormone stanniocalcin 
were not affected by the treatment. In conclusion, the 
chronic administration of the PRL-release inhibitor 
quinagolide decreases milk production in dairy cows. 
The effect is likely the result of the reduced release of 
milking-induced PRL and is modulated at the level of 
the gland by milking frequency. 
 Key words:   lactation ,  milking frequency ,  leptin ,  stan-
niocalcin 
 INTRODUCTION 
 As its name implies, prolactin (PRL) is the most 
important hormone for the control of lactation. This 
hormone is known to be mammogenic and lactogenic 
in both monogastric and ruminant mammals. In most 
mammals, the suppression of PRL strongly inhibits 
lactation (Taylor and Peaker, 1975; Flint and Gardner, 
1994). However, the involvement of PRL in the control 
of ruminant lactation is less clear. Plaut et al. (1987) 
did not observe any increase in milk production by 
cows when PRL was injected for 14 d in early lactation, 
although another study reported a limited increase in 
goats (Knight, 1993). The short-term administration 
before parturition of bromocriptine, a dopamine ago-
nist that suppresses PRL release, reduced postpartum 
milk production in goats (Forsyth and Lee, 1993) and 
cows (Akers, 2002). However, similar treatments ap-
plied during established lactation have produced small 
or no effects on milk yield (Knight, 1993). 
 Milking and suckling induce an important increase 
in PRL in the blood of the female. This effect is not 
related to the milk harvest itself, as it can be induced 
in nonlactating animals by nipple stimulation (Akers 
and Lefcourt, 1983). This neuroendocrine reflex is 
poorly understood, but it is known that the amount of 
PRL released decreases as lactation advances (Fuchs 
et al., 1984) and that suckling is more efficient than 
milking at inducing the reflex (Lupoli et al., 2001). 
Although the basal PRL level is not clearly associated 
with the amount of milk produced, milking-induced 
PRL release is correlated with the level of milk produc-
tion in both cows and mice (Koprowski and Tucker, 
1973; Akers, 2002). In addition, antiapoptotic effects 
of PRL have been reported in the mammary gland of 
rodents (Travers et al., 1996; Flint et al., 2006) and 
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bovine mammary explants (Accorsi et al., 2002). It is 
therefore possible that PRL, especially milking-induced 
PRL, plays an important role in lactation persistency 
by limiting the loss of secretory cells and maintaining 
cell differentiation.
Quinagolide is a compound that binds specifically to 
the lactotroph dopamine D2 receptor, decreasing the 
synthesis and release of PRL (Brownell, 1996). Unlike 
the ergot alkaloid bromocriptine, which was used in 
early studies on PRL action in cows, quinagolide has 
little affinity for serotonin and α-adrenergic binding 
sites (Brownell, 1998). In animal models, quinagolide 
has a longer half-life, has fewer side effects, and is 
200 times more potent than bromocriptine in terms of 
inhibiting lactation (Brownell, 1998). Therefore, the 
objective of this study was to evaluate whether PRL 
is galactopoietic in the bovine by chronically inhibiting 
its secretion with quinagolide.
MATERIALS AND METHODS
The ethical aspects of the care of the animals used 
in this study were in compliance with the relevant 
guidelines and licensing requirements, as defined by 
the French Ministry for Agriculture in accordance with 
French regulations (Decree No. 2001-464, May 29, 
2001).
Experimental Design
Ten multiparous Holstein cows averaging 62 d in 
milk were used in this study. The cows were housed 
at the Méjusseaume experimental dairy farm of INRA 
UMR1080 Production du lait (Le Rheu, France). Cows 
were fed ad libitum with a diet containing (on a DM 
basis) 65% corn silage, 15% alfalfa silage, 18.5% supple-
ment, and 1.5% mineral supplement. Feed intake and 
milk production were recorded daily during the last 
2 wk before the initiation of the treatments (pretreat-
ment period) and during the treatment period. Each 
cow’s BW was determined in wk −2, 1, 3, 6 and 8 (rela-
tive to treatment initiation). During the pretreatment 
period and the first 8 wk of the treatments, all quarters 
were milked twice daily.
During the 9-wk treatment period, 5 of the cows 
received daily (at 1000 h) intramuscular injections of 
1 mg quinagolide (Ferring, Wallisellen, Switzerland), 
and the other 5 received water injections (control treat-
ment). One control cow was treated for mastitis. She 
was removed from the experiment and her data were 
discarded. During the last treatment week, differential 
milking was applied, with one udder half milked once a 
day (1×) and the other twice a day (2×).
Milk yield was recorded at each milking. During the 
differential milking, milk yield was measured and col-
lected by udder halves. Individual milk samples were 
collected 3 times a week to determine milk composition. 
In addition, aliquots of the milk samples were skimmed 
by centrifugation (15 min, 1,000 × g, 4°C) and frozen 
once a week. Those samples were used to determine 
levels of milk gelatinase [matrix metalloproteinase 
(MMP)-2 and MMP-9] activity, BSA, and stanniocal-
cin-1 (STC-1).
To determine hormonal release, jugular blood samples 
were taken in wk −1, 1, 4 and 8. A silastic catheter (Sil-
clear medical-grade silicone tubing, i.d. 1.02 mm, o.d. 
2.16 mm; Degania Silicone, Degania Bet, Israel) was 
inserted into a jugular vein of each cow the day before 
the first blood sampling and remained there for the 
duration of the study. The blood samples were taken 
before and during a.m. milking (at −2, 1, 2, 5, 10, and 
15 min after milking machine attachment) using Mon-
ovette syringes coated with EDTA and sodium heparin 
(Sarstedt, Nümbrecht, Germany). An additional sample 
was collected weekly 1 h after the milking into heparin-
coated tubes to determine concentrations of glucose, 
lactose, urea, NEFA, leptin, and STC-1. Plasma was 
separated by centrifugation at 4°C and 3,000 × g for 
15 min and then stored at −20°C for later analysis.
Analyses
Milk protein and fat contents were determined by a 
commercial laboratory using infrared analysis (Lillab, 
Châteaugiron, France). Milk lactose and casein were 
determined once a week as described by Hurtaud et 
al. (1993). The BSA concentration of the milk was 
determined as described by Tremblay et al. (2009). 
Milk gelatinase activity was determined using gelatin 
zymography, with zymograms performed as described 
by Tremblay et al. (2009).
Plasma PRL concentration was measured using an 
indirect competitive ELISA (Kollmann et al., 2008). 
The intraassay variability was <5% and the interassay 
variability was <12%. Plasma concentration of oxytocin 
was measured using the enzyme immunoassay method 
(Marnet et al., 1994). The detection limit was 7 pg/mL, 
the intraassay CV was 7%, and the interassay CV was 
8%. Plasma leptin was determined using RIA (Ehrhardt 
et al., 2000). The intraassay CV was 5.6%, and the in-
terassay CV was 2.9%. Milk and plasma concentrations 
of STC-1 were determined using RIA as described by 
De Niu et al. (2000) and validated for bovine STC-1 
(Paciga et al., 2002) with inter- and intraassay CV of 
8.6 and 7.5%, respectively. Plasma (from EDTA-coated 
tubes) concentration of IGF-1 was determined by RIA 
(Vicari et al., 2008).
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Plasma (from heparin-coated tubes) concentrations 
of glucose, urea, NEFA, and lactose were measured on 
a multiparameter analyzer (KONE Instruments Corp., 
Espoo, Finland). Commercial kits for glucose (kit glu-
cose hexokinase, Diagnostics, Meylan, France), NEFA 
(NEFA C test, Wako, Oxoid, Davdilly, France), urea 
(ref. 11703, Thermo Electron, Cergy-Pontoise, France). 
and lactose (kit for lactose/d-galactose; Roche Diag-
nostics, Meylan, France) were used.
Statistical Analyses
Data were analyzed by ANOVA using the MIXED 
procedure of SAS (SAS Institute Inc., Cary, NC) 
with the REPEATED statement. Time was used as a 
repeated effect, and cow(treatment) was used as the 
subject. For all variables except oxytocin, the data 
obtained during the pretreatment period were aver-
aged and used as a covariate. The amounts of PRL 
and oxytocin released into the blood at milking were 
calculated by determining the areas under the curves. 
Differential milking data from the last 3 d of the pe-
riod were averaged and analyzed by using the MIXED 
procedure with a REPEATED statement. Quinagolide 
treatment and milking frequency were the main effects 
and cow(treatment) was used as the subject. The effect 
of quinagolide treatment within milking frequency was 
evaluated with the slice option on the interaction term 
in the LSMEANS statement. The relationship between 
several parameters was evaluated using the CORR pro-
cedure of SAS. Differences were considered statistically 
significant when P < 0.05.
RESULTS
The amount of PRL released at milking was reduced 
by quinagolide (P < 0.05). In wk 1, 4, and 8, respec-
tively, the amount released averaged 32, 12, and 20% of 
the wk −1 amount in the quinagolide-treated cows and 
104, 83, and 73% of the wk −1 amount in the control 
cows. The basal PRL concentration was not affected by 
the quinagolide treatment.
Milk production declined faster in quinagolide than 
control cows (P < 0.05; Figure 1). Milk production of 
quinagolide-treated cows was 5.3 kg/d less than that of 
control cows during the last 4 wk of treatment. Milk fat 
content was not affected by treatment (Table 1). Milk 
protein content increased by 10% during the experi-
ment (P < 0.001) but was not affected by treatment 
(Table 1). Accordingly, milk fat and protein yields 
were decreased (P < 0.01 and 0.05, respectively) in 
the quinagolide-treated animals. Lactose content of the 
milk was similar for both groups of animals for the first 
4 wk, but was reduced (P < 0.05) in the quinagolide-
treated animals in wk 5, 6, and 7 (Figure 2). Lactose 
yield was also reduced by the quinagolide treatment (P 
< 0.05; Table 1). Casein content of the milk was not 
affected by the treatment.
The cows treated with quinagolide ate less than the 
control cows (P < 0.05), with DMI averaging 22.8 ± 
0.5 and 21.1 ± 0.4 kg/d for the control and quinagolide-
Journal of Dairy Science Vol. 94 No. 3, 2011
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Figure 1. Milk production of dairy cows injected with water 
(—♦—; n = 4) or quinagolide (------; 1 mg/d; n = 5) for 8 wk. 
Quinagolide significantly reduced milk production (P < 0.05). Data 
are presented as least squares means ± SEM.
Table 1. Effect of the injection of water (control; n = 4) or quinagolide (1 mg/d; n = 5) for 8 wk on milk 





Control Quinagolide Trt Trt × time
Fat (%) 4.03 4.18 0.67 NS2 NS
Fat (kg/d) 1.52 1.38 0.25 0.01 NS
Protein (%) 3.07 3.16 0.63 NS NS
Protein (kg/d) 1.15 1.04 0.32 0.04 NS
Lactose (kg/d) 1.78 1.54 0.60 0.03 NS
Casein (%) 2.17 2.27 0.61 NS NS
1Data are least squares means for the treatment period.
2P > 0.15.
treated cows, respectively. However, the cows in both 
groups gained weight, and no treatment effect on BW 
was observed (data not shown). Blood concentrations 
of NEFA, glucose, and urea averaged 152 ± 28 and 176 
± 24 μmol/L; 658 ± 1 and 674 ± 1 mg/L; and 226 ± 
12 and 238 ± 11 mg/L for the control and quinagolide-
treated cows, respectively. They were not affected by 
treatment.
Milking-induced oxytocin release was monitored after 
1 wk of treatment and was not affected by treatment (P 
> 0.15). For the control and quinagolide-treated cows, 
respectively, the amount of oxytocin that was released 
averaged 520 ± 78 and 545 ± 107 pg/mL per minute, 
and the maximum concentration that was reached aver-
aged 106 ± 37 and 116 ± 34 pg/mL.
Plasma concentration of IGF-1 increased during the 
treatment period (P < 0.01) but was not affected by 
treatment, averaging 110 ± 10 and 124 ± 9 ng/mL for 
the control and quinagolide-treated cows, respectively. 
Similarly, plasma concentrations of leptin and STC-1 
increased slightly over time (P < 0.05) but were not 
affected by treatment, averaging 2.5 ± 0.1 and 2.4 ± 
0.1 ng/mL (leptin) and 2.66 ± 0.06 and 2.65 ± 0.05 ng/
mL (STC-1) for the control and quinagolide-treated 
cows, respectively. Milk concentration of STC-1 was 
not affected by time or the treatment, averaging 0.91 
± 0.18 and 1.01 ± 0.15 ng/mL for the control and 
quinagolide-treated cows, respectively.
Mammary tight-junction patency was monitored by 
analyzing blood lactose and milk BSA concentrations. 
Blood lactose was not affected by treatment, averaging 
23.0 ± 3.2 and 24.2 ± 2.9 mg/L for the control and 
quinagolide-treated cows, respectively. Accordingly, 
BSA concentration was lower than the detection limit 
(0.1 mg/mL) in the milk samples of 2× udder half for 
both control and quinagolide-treated cows, indicating 
no opening of the tight junctions (data not shown).
Gelatin zymography showed the presence of prote-
olytic activity at the apparent molecular weights of 
107 kDa in all the milk samples and at 60 kDa in 60% 
of the samples. The two proteolytic bands were not 
affected by time or treatment (data not shown).
Correlations between endocrine parameters and milk 
production were calculated. The highest correlation co-
efficients were obtained with the amounts (areas under 
the curves) and peak values of milking-induced PRL 
release (Table 2). Interestingly, the coefficients were 
similar in the control and quinagolide-treated cows. No 
significant correlations were found between IGF-1 or 
STC-1 concentrations and milk production (data not 
shown).
Differential milking resulted in a reduction in milk 
production in the udder half that was milked 1× (P < 
0.001; Figure 3). The inhibitory effect of quinagolide 
was maintained in the udder half that was milked 
2× (P < 0.05) but was lost in the half milked 1×. 
Similarly, the inhibitory effects of quinagolide on milk 
protein and fat yields were maintained in the udder 
half that was milked 2× (P < 0.05; Table 3) but not in 
the half milked 1×. Reducing the milking frequency to 
1× caused increases in milk fat contents as well as in 
matrix metalloproteinase (MMP)-2 and MMP-9 activ-
ity (P < 0.05; Table 3). Milk BSA content were below 
the detection limit for 2× quarters but averaged 0.28 
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Figure 2. Lactose concentration in milk from dairy cows injected 
with water (—♦—; n = 4) or quinagolide (------; n = 5) for 8 wk. 
Quinagolide significantly reduced milk lactose concentration in wk 5, 
6, 7 (*P < 0.05) and 8 (†P < 0.1). Data presented are least squares 
means ± SEM.
Table 2. Correlation between milking-induced prolactin release in blood and milk production1 
Item2
All animals Control Quinagolide
R P-value R P-value R P-value
AUC 0.57 0.001  0.64 0.01  0.61 0.005
Peak 0.56 0.001  0.61 0.02  0.64 0.005
1R = Pearson correlation coefficient; AUC = area under the curve.
2AUC = area under the curve of prolactin concentration in the plasma during the first 15 min following milking 
machine attachment; Peak = maximum prolactin concentration in the plasma during the first 15 min following 
milking machine attachment.
± and 0.21 mg/mL in 1× quarters for the control and 
quinagolide-treated cows, respectively.
DISCUSSION
In this experiment, we observed that the dopamine 
D2 receptor agonist quinagolide inhibited milking-in-
duced PRL release in lactating cows. Although already 
used in humans for this purpose, quinagolide had never 
been tested in cows. The main physiological control 
of PRL secretion is exerted by the inhibitory action 
of dopamine on the lactotrophs of the anterior pitu-
itary (Torre and Falorni, 2007). Dopamine is secreted 
in the hypothalamus through the tuberoinfundibular 
dopamine pathway and reaches the pituitary through 
a portal vascular system. It has been proposed that 
suckling reduces the activity of the neurons in the 
tuberoinfundibular dopamine pathway, enabling the 
release of PRL into the bloodstream (Li et al., 1999). 
Accordingly, administration of the dopamine antago-
nist fluphenazine to lactating cows has induced PRL 
release with a magnitude comparable to that induced 
by milking (Ahmadzadeh et al., 2006).
Quinagolide did not completely prevent milking-
induced PRL release. The dose used in this study 
(1 mg/d) was equivalent, on a BW basis, to the dose 
used to normalize PRL in hyperprolactinemic women 
(0.075 mg/d; Barlier and Jaquet, 2006). With a half-
life of 22 h, quinagolide is administered once a day in 
women (Barlier and Jaquet, 2006). In the present study, 
the cows were injected at 1000 h and PRL concentra-
tion was evaluated at milking the following morning 
(about 21 h later). If the half-life in cows is in the same 
range as in humans, the circulating concentration at 
that time would already have been less than half of its 
maximum. Therefore, it is likely that inhibition was 
greater at the evening milking. Accordingly, greater 
inhibition of milking-induced PRL release was observed 
when cows were also injected after the evening milking 
(Lollivier et al., 2009).
The administration of quinagolide reduced milk 
production and yield of milk components. The effect 
of another dopamine agonist, bromocriptine, on milk 
production was tested previously in dairy ruminants. In 
their first experiment, Karg et al. (1972) injected 2 cows 
with increasing doses (20 to 160 mg) of bromocriptine 
for 3 d and observed an inhibition of PRL without any 
effect on milk production. Smith et al. (1974) treated 
5 cows with 80 mg of bromocriptine for 2 d without 
affecting milk production. In their second experiment, 
however, Karg et al. (1972) injected 2 cows for 7 d (5 d 
at 150 mg followed by 2 d at 75 mg) and reported a 10 
Journal of Dairy Science Vol. 94 No. 3, 2011
LACASSE ET AL.1306
Figure 3. Effect of injecting water (white bars; n = 4) or quina-
golide (black bars; 1 mg/d; n = 5) and differential milking [one udder 
half milked once a day (1×) and the other milked twice a day (2×)] 
on milk production of dairy cows. The udder half that was milked 1× 
produced less milk than the udder half milked 2× (P < 0.001). The 
inhibitory effect of quinagolide was maintained in the udder half that 
was milked 2× (P < 0.05) but lost in the half milked 1× (P > 0.15). 
Data are presented as least squares means ± SEM. 
Table 3. Effect of the injection of water (control; n = 4) or quinagolide (1 mg/d; n = 5) and differential milking [one udder half milked once a 
day (1×) and the other milked twice a day (2×)] on milk composition and gelatinase activity in dairy cows 
Item
Control Quinagolide P-value1
1× 2× 1× 2× MF Trt Trt × MF Trt(1×) Trt(2×)
Fat (%) 4.74 4.17  4.50 4.28  0.03 NS2 NS NS NS
Fat (kg/d) 0.55 0.81  0.49 0.65  0.001 0.02 0.20 NS 0.02
Protein (%) 3.37 3.22  3.41 3.36  0.02 NS 0.16 NS NS
Protein (kg/d) 0.38 0.62  0.37 0.52  0.001 0.06 0.12 NS 0.03
MMP-23,4 60.8 6.1  60.8 8.6  0.02 NS NS NS NS
MMP-95 133.9 98.1  112.9 103.3  0.03 NS NS NS NS
1MF = milking frequency; Trt = treatment; Trt(1×) or Trt(2×) = effect of quinagolide treatment in the udder half that was milked once a day 
or twice a day.
2P > 0.20.
3MMP = matrix metalloproteinase.
4Proteolytic activity (integrated density values × 10−3) at an apparent molecular weight of 60 kDa on a gelatin zymogram.
5Proteolytic activity (integrated density values × 10−3) at an apparent molecular weight of 107 kDa on a gelatin zymogram.
to 20% decline in milk production. In goats, an early 
study did not report an effect of bromocriptine on milk 
yield (Hart, 1973), whereas a subsequent study reported 
a 21% decrease in milk production after 8 d (Knight et 
al., 1990). The inconsistent effects of bromocriptine on 
milk production seen in earlier experiments were prob-
ably related to the short period of administration and 
the very small number of experimental animals.
In the present study, milk production was correlated 
with the amount of PRL released at milking, and this 
relationship was maintained within each treatment 
group. This correlation between milking-induced PRL 
release and milk production, previously reported by Ko-
prowski and Tucker (1973), indicates that the effect of 
quinagolide on milk production is likely to be mediated 
by PRL inhibition. The classical way to demonstrate 
the action of a hormone is to remove its source, observe 
the changes induced, and try to restore the function by 
hormone replacement. In a previous study, hypophysec-
tomy of lactating goats caused a sharp decline in milk 
production that required PRL and other hormones to 
be restored. Once milk production was back to normal, 
however, the PRL treatment could be discontinued 
without milk production decreasing again (Cowie et 
al., 1964). The logical conclusion of that experiment 
was that PRL is lactogenic but not galactopoietic 
in goats. However, the goats were given a large dose 
(12.5 mg/d) of bovine growth hormone, and its removal 
depressed milk production (Cowie et al., 1964). This 
growth hormone was pituitary-derived and might have 
been contaminated with PRL as reported by Skarda et 
al. (1982). Plaut et al. (1987) injected 8 cows for 14 d 
with 120 mg of PRL without affecting milk production. 
Although the injections increased plasma PRL 2- to 
5-fold, they considerably reduced the milking-induced 
release of PRL. Conversely, the injection of a much 
smaller dose of PRL (1 μg/kg of BW) twice a day for 
the first 3 wk of lactation increased milk production 
(Wall et al., 2006). In goats, recombinant PRL injec-
tions increased milk yield by over 10%, an increase that 
was comparable and additive to that elicited by growth 
hormone (Flint and Knight, 1997). Further evidence of 
the galactopoietic action of PRL is provided by the fact 
that a long-day photoperiod was found to increase PRL 
concentration and milk production (Bilodeau et al., 
1989), whereas administration of melatonin for 12 wk 
decreased PRL and milk production (Auldist et al., 
2007). In all, a good body of evidence now exists indi-
cating that PRL is galactopoietic in dairy ruminants.
The effect of the treatment in the present study was 
modulated by milking frequency, with the inhibitory 
effect of quinagolide lost in the udder half that was 
milked 1×. In goats, a unilateral increase in milking 
frequency increased the milk response to PRL admin-
istration (Knight, 1993). McKinnon et al. (1988) ob-
served that increasing the milking frequency increased 
the PRL-binding capacity of the mammary gland. 
Accordingly, in cows milked differentially (one udder 
half milked 1× and the other 3×), it was observed 
that the gene expression of long and short isoforms of 
PRL receptors was higher in the glands milked more 
frequently (Bernier-Dodier et al., 2010). That suggests 
that another important determinant of PRL action is 
mammary tissue responsiveness, a conclusion that is 
further supported by the fact that a short-day photope-
riod during the dry period was found to increase both 
the expression of PRL receptors and subsequent milk 
production (Auchtung et al., 2005). Nevertheless, it is 
also possible that milk accumulation and tight junction 
disruption induced by 1× milking may have masked the 
treatment-induced responses.
A decrease in feed intake was observed in the 
quinagolide-treated cows. The injection of female rats 
with bovine PRL increased feed intake and BW gain 
(Byatt et al., 1993). The suckling stimulus activates 
neuropeptide Y neurons in the dorsomedial nucleus of 
the hypothalamus, an effect that is reduced by bro-
mocriptine treatment (Li et al., 1999). Although based 
on results from other species, one study proposed that 
neuropeptide Y plays an important role in the increase 
in feed intake in early lactation (Ingvartsen and An-
dersen, 2000). It is therefore possible that inhibition of 
PRL by quinagolide is responsible for the reduction in 
feed intake. The reduced feed intake did not affect BW 
gain or blood metabolite concentrations and therefore 
probably played a minor role in the reduction of milk 
production.
Feuermann et al. (2006) proposed that PRL affects 
leptin secretion by the mammary fat pad, which, in 
turn, increases the lactogenic action of PRL on mam-
mary epithelial cells. In the present study, the circulat-
ing leptin concentration was not affected by the qui-
nagolide treatment. In the lactating bovine mammary 
gland, the mammary fat pad is small and not in direct 
contact with the epithelium, making the diffusion of a 
factor from the fat pad to the epithelial tissue unlikely. 
Therefore, the absence of any effect of the PRL inhibi-
tor on the blood leptin concentration does not support 
the proposal of Feuermann et al. (2006).
Milk concentration of STC-1 was not affected by qui-
nagolide. Stanniocalcin-1 is a hormone that was first 
discovered in fish and recently in mammals (Wagner 
et al., 1995). In fishes, PRL and STC-1 have opposing 
actions on calcium homeostasis (Flik et al., 1994). In 
previous experiments where milk production was re-
duced by injecting estrogen (Delbecchi et al., 2005), by 
unilaterally stopping milking (Tremblay et al., 2009), 
or by decreasing milking frequency (Bernier-Dodier et 
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al., 2010), increased STC-1 in milk was observed. In 
those experiments, however, indicators of active involu-
tion were also upregulated, suggesting a link between 
these STC-1 and involution. In the present experiment, 
those indicators were not affected by quinagolide, and 
that probably explains why STC-1 was not affected.
Moderate gelatinase activity was detected in milk. 
According to Raulo et al. (2002), the 107-kDa band cor-
responds to MMP-9 and the 60-kDa band corresponds 
to MMP-2. These activities have been shown to increase 
in milk of the involuting gland during once-a-day milk-
ing (Bernier-Dodier et al., 2010), late lactation (Miller 
et al., 2006), and milk stasis (Tremblay et al., 2009). In 
this experiment, MMP activities were increased by 1× 
milking but not by quinagolide. Therefore, it is unlikely 
that quinagolide treatment increased the remodeling 
of the mammary tissue via metalloproteinase activity 
induction.
In conclusion, the data presented here support the 
hypothesis that PRL is galactopoietic in dairy cows. 
The hormone appears to directly affect the mammary 
gland, but the response to PRL appears to be modulat-
ed at the mammary gland level by milking frequency.
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